Evidence map›Paper›PMID 37007773›Full record

ArticleFrontiers in medicine2023

Serological testing for Hansen's disease diagnosis: Clinical significance and performance of IgA, IgM, and IgG antibodies against Mce1A protein.

Filipe Rocha Lima, Mateus Mendonça Ramos Simões, Gabriel Martins da Costa Manso, Diana Mota Toro, Vanderson Mayron Granemann Antunes, Giovani Cesar Felisbino, Gabriela Ferreira Dias, Lee W Riley, Sérgio Arruda, Natália Aparecida de Paula and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Filipe Rocha LimaHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Mateus Mendonça Ramos SimõesHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Gabriel Martins da Costa MansoHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Diana Mota ToroDepartment of Clinical, Toxicological and, Bromatological Analyses, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Vanderson Mayron Granemann AntunesHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Giovani Cesar FelisbinoHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Gabriela Ferreira DiasHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Lee W RileyDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, United States.
Sérgio ArrudaAdvanced Public Health Laboratory, Gonçalo Moniz Institute, Oswaldo Cruz Foundation, Salvador, Brazil.
Natália Aparecida de PaulaHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Helena Barbosa LugãoDermatology Division, Department of Internal Medicine, National Referral Center for Sanitary Dermatology and Hansen's Disease, University Hospital, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Fernanda André Martins Cruz PerecinDermatology Division, Department of Internal Medicine, National Referral Center for Sanitary Dermatology and Hansen's Disease, University Hospital, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Norma Tiraboschi FossHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Marco Andrey Cipriani FradeHealing and Hansen's Disease Laboratory, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRFundação Oswaldo Cruz · BRUniversity of California, Berkeley · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hansen's disease (HD) is an infectious, treatable, and chronic disease. It is the main cause of infectious peripheral neuropathy. Due to the current limitations of laboratory tests for the diagnosis of HD, early identification of infected contacts is an important factor that would allow us to control the magnitude of this disease in terms of world public health. Thus, a cross-sectional study was conducted in the Brazilian southeast with the objective of evaluating humoral immunity and describing the accuracy of the immunoassay based on IgA, IgM, and IgG antibodies against surface protein Mce1A of

Indexed as

antibodiesdiagnosisHansen’s diseaseMce1Aserologicaltesting

Identifiers

PMID37007773
PMCPMC10062478
OpenAlexW4327612765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.